New Data Show ImpediMed’s Lymphedema Prevention Program Reduces Incidence of Chronic Lymphedema in Breast Cancer Patients and Survivors
CARLSBAD, Calif. and BRISBANE, Australia, Dec. 1, 2020 /PRNewswire/ — ImpediMed Limited (ASX: IPD), a global medical technology company using bioimpedance spectroscopy (BIS) to generate powerful data to improve patient health, today announced the publication of a new study demonstrating that the company’s Lymphedema Prevention Program reduces the incidence of chronic breast cancer-related lymphedema in breast cancer patients and survivors.
Published in Breast Cancer Research and Treatment, the meta-analysis involving 50 studies and more than 67,000 breast cancer patients confirms that routine monitoring for early detection of lymphedema using ImpediMed’s L-Dex® technology, combined with early intervention, cuts the relative rate of chronic breast cancer-related lymphedema by as much as 81%.
The publication is available online here.
“The results of this analysis confirm the utility of L-Dex as part of breast cancer-related lymphedema screening in reducing rates of chronic breast cancer-related lymphedema as compared to circumference measures (i.e., tape measure) or no monitoring,” said Chirag Shah, MD, Radiation Oncologist, Director of Clinical Research and Director of Breast Radiation Oncology in the Department of Radiation Oncology at the Cleveland Clinic and primary author of the study. “What is striking is the reduction with L-Dex surveillance and intervention that showed an 81% relative decrease in breast cancer-related lymphedema as compared to circumference measures. The fact that the analysis is both statistically and clinically significant stresses the need for widespread prospective surveillance of breast cancer patients and survivors with L-Dex.”
Breast cancer-related lymphedema occurs when the lymphatic system is damaged by surgical, radiation or chemotherapy treatments for breast cancer. The risk of developing lymphedema ranges from 6% to 42% depending on the treatment approach. Patients suffering from lymphedema commonly experience swelling in their arms and hands that can interfere with activities of daily life and work.
Treatments, including compression garments and therapy, can be costly to patients. On average, breast cancer survivors with lymphedema spend an extra $3,325 per year on medical care and productivity losses as compared to survivors without lymphedema. If left untreated, lymphedema can lead to infection and become a chronic lifelong condition.
In 2019, ImpediMed introduced a comprehensive Lymphedema Prevention Program to help educate healthcare providers and patients that with proper protocols in place, subclinical lymphedema can be detected and managed before it becomes a debilitating, chronic condition.
This program utilizes ImpediMed’s Test, Trigger, Treat® protocol for early detection and intervention of cancer-related lymphedema. Routine lymphedema testing of cancer survivors uses the company’s FDA-cleared SOZO® device with BIS (L-Dex) technology, which measures extracellular fluid. A significant increase in a patient’s L-Dex score is a trigger to evaluate the patient and initiate intervention.
“These findings are an important step forward in our goal to eliminate breast cancer-related lymphedema,” said Richard Carreon, Managing Director and CEO of ImpediMed. “The meta-analysis demonstrates the effectiveness of early detection with L-Dex and intervention in reducing breast cancer-related lymphedema. This Level 1 evidence is a key step in making L-Dex the standard of care for all patients at risk of developing breast cancer-related lymphedema.”
ImpediMed’s PREVENT Trial demonstrated that routine monitoring with L-Dex combined with at-home intervention resulted in a 95% reduction in lymphedema progression at one year. Today, L-Dex is the only non-invasive, reliable, validated tool to help clinicians identify subclinical lymphedema.
The company’s SOZO digital health platform can measure a patient’s L-Dex score with a simple, painless 30-second scan. Monitoring L-Dex scores allows clinicians across multiple specialties to provide individualized, proactive care that can help improve patient outcomes.
To view the meta-analysis, visit here.
Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif., and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphedema of the arm and leg in women and the leg in men. For additional information, visit www.impedimed.com.